INSM
NASDAQ · Biotechnology
Insmed Inc
$120.82
-0.18 (-0.15%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
-16.89%
YTD
-31.79%
Open$121.00
Previous Close$121.00
Day High$122.48
Day Low$119.09
52W High$212.75
52W Low$90.39
Volume—
Avg Volume2.04M
Market Cap26.21B
P/E Ratio—
EPS$-4.10
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$168.11
Below
SMA 200
$139.54
Below
RSI (14)
54.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
30 analysts
Price Target
+18.7% upside
Current
$120.82
$120.82
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 665.43M | 492.18M | 44.36B |
| Net Income | -1,401,026,566 | -932,636,027 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,361,521,351 | -956,690,298 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |